Finally, the effectiveness of both codeine and cannabis for relieving moderate chronic pain seems to be limited, with no Cochrane Reviews supporting such a claim as primary drug of choice (e.g. [12, 13] ). Perhaps this judgement about effectiveness is premature for cannabis, with research to collect better evidence only now commencing, but it reflects the current evidence base.
However, from a public health point of view, given the abuse potentials of both drugs involved, perhaps solutions should be sought with non-pharmacological therapies or with medications with less abuse potential than opioids or cannabis. The history of opioids in pain medication in North America should be a lesson. Despite limited evidence for effectiveness, prescription opioids were seen as a wonder drug, especially for pain management, with rapidly accelerating use to the point where they contributed markedly to a high level of opioid addiction on the population level and a major public health crisis [14] , and decreasing life expectancies [15, 16] . As a result, new national guidelines for opioid pain prescription stress non-pharmacological therapies and non-opioid medication as first-line treatment [17] .
We should not repeat this history with yet another wonder drug installed before proper evidence for effectiveness and well-documented unintentional consequences. Given the current evidence, there is no good reason not to start pain management with non-pharmacological therapies, but there are good reasons to limit the use of drugs with high abuse potential to the highest degree possible.
Declaration of interests
None.
